Novartis agreed to acquire Pikavation Therapeutics, a Synnovation subsidiary, for $2 billion up front to secure next‑generation pan‑mutant PI3Kα inhibitors including SNV‑4818. The deal could reach $3 billion with milestones and is aimed at bolstering Novartis’s breast‑cancer portfolio as rivals press on PI3Kα targets. Novartis framed the purchase as a strategic move to defend and upgrade its existing offerings in a competitive tumor‑targeted space. Industry note: PI3Kα inhibitors target oncogenic PIK3CA mutations common in certain breast cancers; next‑generation compounds seek to improve efficacy while reducing toxicity seen with older agents.